ClinicalTrials.gg
Enrolling by invitationNCT06421402Updated May 20, 2024

K-HEALTH in AIR - Barcelona Pilot - Cohort

An observational study in Severe Asthma and COPD, sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Enrolling by invitation at 1 site in Spain. Open to participants aged Up to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-20.

Sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
Up to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 222 studies in Asthma with a site in Spain — 30 open to participants now, 42 under way, 13 of them phase 3. Asthma · Spain.

Planned enrollment
28th of 52
200 · median 218
Started
2023
with 15 others
Observational
52 of 222
8 open now
Primary completion
2025-12
later than 5 of 41 live
Registered
194th of 222
by date

Among the 222 studies in Asthma with a site in Spain, this one is the 28th largest by planned enrollment of the 52 observational ones that give a count, is one of 16 that started in 2023, is one of 52 observational ones, reaches primary completion later than 5 of the 41 other live ones, and was the 194th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

30 of the 222 studies in Asthma with a site in Spain are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: Up to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Asthma with a site in Spain, or all of them as a file.
02

Study summary

The study protocol is part of the European (EU) project "Knowledge for improving indoor AIR quality and HEALTH" (K-HEALTHinAIR, 2022-2026 - registry 101057693), which focuses on enhancing our understanding of how poor indoor air quality (IAQ) affects human health. Specifically, the project aims to identify IAQ determinants of adverse health events and to explore the development of cost-effective strategies for the precise monitoring and improvement, of IAQ across Europe.

With the current study protocol, the Barcelona Pilot, at the Integrated Health District of Barcelona-Esquerra (AISBE, 520 k citizens), is conducting a cohort study over a two-year period (January 2024 to December 2025) to explore the relationships between IAQ (assessment of chemical pollutants in patients' homes) and health status (acute episodes) in multimorbid patients with chronic respiratory diseases (asthma and Chronic Obstructive Pulmonary Disease - COPD) over a two-year period.

The protocol investigates the effectiveness of customized interventions across four critical areas: i) Advanced lung function testing, ii) Continuous IAQ monitoring, iii) Advanced digital support to innovative clinical processes, and iv) Predictive modeling for early identification and management of exacerbations. The ultimate objective is to design and evaluate an innovative integrated care service aiming at enhancing both IAQ and the management of multimorbid patients with chronic obstructive respiratory diseases, with focus on COPD and severe asthma.

Read the detailed description

The study is structured as a comprehensive two-phase approach. From January to December 2024 (Phase I) the protocol focuses on the assessment, and refinement, of the four core components of the study: i) Enhanced lung function testing, ii) IAQ home monitoring, iii) Advanced digital support to innovative clinical processes, and iv) Predictive modelling for early detection and management of exacerbations. The main outcome at the end of Phase I is the design of an innovative integrated care service aiming at enhanced management of exacerbations and reduction of unplanned hospitalizations in high-risk patients.

From January to December 2025 (Phase II), the protocol aims to refine the novel clinical process, including the four core components alluded to above, as well as to evaluate the potential for healthcare value generation and scalability/transferability of the new integrated care service.

PHASE I (2024):

  1. Enhanced Lung Function Testing: Adoption of oscillometry (forced oscillation technique) to measure respiratory system resistance and reactance, as a complementary tool of forced spirometry, exploring its potential for patients' monitoring and management of exacerbations.
  2. Continuous Monitoring of IAQ at patients' homes: Assessment of advanced monitoring systems in patients' homes to continuously track air quality parameters, enabling the identification of environmental triggers linked to respiratory exacerbations.
  3. Advanced Digital Support to innovative clinical processes with a two-fold aim: i) patient's empowerment for self-management of his/her condition, and ii) enhancing the role of the nurse case manager for early detection and management of exacerbations promoting share care agreements between the patient and the reference doctor (primary care physician and/or specialist). To this end, adoption of an Adaptive Case Management (ACM) Approach constitutes a key element.
  4. Predictive Modeling: Development, and refinement, of machine learning-based modelling for early detection and management exacerbations. Key input data in the modelling approach will be: i) Clinical information (symptoms, Patient Reported Outcome Measures - PROMs), ii) Lung function testing, and iii) Patient's self-capturing physiological data through wrist sensors (health rate, heart rate variability and physical activity). Moreover, the impact of IAQ monitoring in the modelling will be explored.

The implementation, and refinement, of the four components alluded to above, as well as the design of the novel integrated care service, will be done with active engagement of patients, healthcare professionals, and other stakeholders in a co-design process using the Plan-Do-Study-Act (PDSA) methodology. Two PDSA cycles, with a six-month duration each, will be undertaken during 2024.

PHASE II (2025):

From January to December 2025, two additional PDSA cycles (six-month duration each) are planned to cover the following objectives:

  1. Refinement of the novel integrated care service for enhanced management of exacerbations, as well as the implementation and continuous assessment of the four core components described in PHASE I.
  2. Assessment of the outcomes of the novel integrated care service using the Quintuple Aim framework, that is, considering: i) Healthcare outcomes, ii) PROMs/Patient Reported Expirence Measures (PREMs), iii) healthcare professionals' engagement, iv) operational costs, and v) assessing equity. Comparison with conventional care will be done using a propensity score matching to elaborate a control group.
  3. Evaluation of the process of deployment of the service using the Consolidated Framework for Implementation Research (CFIR) to identify barriers/facilitators for achieving a sustainable adoption, target candidates for the novel service, as well as potential for service transferability to other sites.

At the end of PHASE II, a mature service design ready for adoption should be available. Besides fulfilment of the objectives of K-Health in Air, the key lessons learned in the two-years period should provide novel insights for enhanced management of chronic patients with multimorbid conditions.

(Enclosed find: i) the Patient's Informed Consent approved by the Ethics Committee, as well as ii) the study protocol approved by the Ethics Committee of the Hosptial Clínic de Barcelona (HCB-2023-0126)).

03

Conditions studied

  • Severe Asthma
  • COPD

Keywords

  • Prevention of Unplanned Hospital Admissions
  • Nurse Case Manager
  • COPD
  • Severe Asthma
  • Integrated Care
  • Digital support
  • Indoor Air Quality
04

Who can participate

Ages eligible
Up to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study is recruiting 80% of participants from seven AISBE primary care facilities, each serving around 20,000 people. Recruitment leverages Catalan Health Surveillance System data to identify potential participants and link them with their primary care physicians, who engage with patients to assess participation willingness and ensure contact throughout follow-up. Initial contact involves a phone call from a nurse case manager to introduce the project and set up a home visit.

The remaining 20% of the cohort, consisting of patients with treatment-resistant asthma, are recruited from the outpatient Severe Asthma Clinics at Hospital Clínic de Barcelona, using a similar approach.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged Maximum 85 years
  • Diagnosed with chronic obstructive pulmonary conditions such as or treatment-resistant asthma.
  • Exhibiting a high burden of co-morbidities, assessed above the 80th percentile of the regional risk stratification pyramid using Adjusted Morbidity Groups (AMG) scoring.
  • Residing in Barcelona-Esquerra, except for treatment-resistant asthma patients, live in any district of the city of Barcelona.

Exclusion criteria

Exclusion Criteria:

  • Dementia.
  • Inability to perform independent daily activities.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Follow-up 200 high-risk chronic respiratory outpatients for 2 years.

    The INTERVENTION (PHASE I, 2024) will have four components: i) Assessment of Lung Function Testing, ii) Monitoring of IAQ at patients' homes (and analysis of the relationships between IAQ and health events), iii) Evaluation of advanced digital support to a novel clinical process to enhance early identification and management of exacerbations (questionnaires, chat, patients' self-capturing sensors, and iv) Development, and refinement, of machine learning-based predictive modelling for supporting clinical decision making. During PHASE II (2025), the INTERVENTION will consist of the assessment (Quintuple Aim) of the novel integrated care service, as well as the evaluation of its potential for scalability (CFIR). See inclusion/exclusion criteria and planned measurements in the enclosed documents.

    Other: Air quality monitoring at patient's home · Other: Questionnaires: Baseline & every six months · Diagnostic Test: Lung function Testing: Baseline & every six months & during exacerbations · Other: EMR & registry data · Device: Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023) · Device: Physiological data - Beat One Watch · Device: Patient Empowerment · Other: Characteristics of exacerbations

  • Control Group

    The control group will be introduced in Phase II (2025) to estimate the potential for healthcare value generation of the novel integrated care service. It will include patients with equivalent characteristics who receive standard of care practice, without the interventions carried out in the cohort group. The control group will be shaped using 1-to-1 propensity score matching techniques. Data from the control group will be obtained from electronic medical records and registry information. In a randomly selected subset of 50 individuals from the control group a Quintuple Aim assessment will be done.

    Other: EMR & registry data

Interventions

  • OtherAir quality monitoring at patient's home

    Indoor Air Quality: - MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3) Outdoor Air Quality: - Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3

  • OtherQuestionnaires: Baseline & every six months

    General surveys: * PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires. * PREMs: Patient-Reported Indicator Survey (PaRIS) Disease specific questionaires: * COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale. * Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22).

  • Diagnostic testLung function Testing: Baseline & every six months & during exacerbations

    * Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) * Forced Oscillation Technique: Impedance, resistance and reactance. Ancillary measurements: Systemic arterial pressure and pulse oximetry.

  • OtherEMR & registry data

    Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases. Registry data: from the Catalan Health Surveillance System (CHSS).

  • DeviceCommunication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)

    Health Circuit: chat, short questionnaires (Likert scale). As needed.

  • DevicePhysiological data - Beat One Watch

    Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))

  • DevicePatient Empowerment

    Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor

  • OtherCharacteristics of exacerbations

    Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.

06

What researchers measure

Primary outcomes

  1. Changes in use of healthcare resources - Unplanned hospital admissions

    Number of unplanned hospital admissions. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

  2. Changes in use of healthcare resources - Exacerbations

    Number and severity of exacerbations. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

  3. Changes in use of healthcare resources - Emergency room visits

    Number of emergency room visits. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

  4. Changes in use of healthcare resources - Primary care visits.

    Number of primary care visits. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

Secondary outcomes

  1. Healthcare costs

    Healthcare costs in € This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

  2. Patient reported experience (PREMs) - Enjoyment of life

    Enjoyment of life: ICEpop CAPability measure for Older people (ICECAP-O) Scored on a scale from 0 to 1, where 0 represents no capability and 1 represents full capability. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  3. Patient reported experience (PREMs) - Resilience

    Resilience: Brief Resilience Scale (BRS) Scores range from 1 to 5, with higher scores indicating greater resilience. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  4. Patient reported experience (PREMs) - Physical functioning

    Physical functioning: 36-Item Short Form Survey (SF-36) Scores range from 0 to 100, where a higher score indicates better health status. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  5. Patient reported experience (PREMs) - Continuity of care

    Continuity of care: Nijmegen Continuity Questionnaire (NCQ) Scores ranging on a Likert scale from 1 to 5. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  6. Patient reported experience (PREMs) - Physiological wellbeing

    Physiological wellbeing: Mental Health Inventory-5 (MHI-5) Scored on a scale of 0 to 100, where higher scores indicate better mental health. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  7. Patient reported experience (PREMs) - Social Participation

    Social Participation: Impact on Participation and Autonomy (IPA) Uses a scoring system based on a Likert scale ranging from 0 to 4 where higher scores indicate greater impairment in participation and autonomy. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  8. Patient reported experience (PREMs) - Person-centeredness

    Person-centeredness: Patient Perceptions of Patient-Centeredness Questionnaire (P3CEQ) Typically uses a Likert scale from 1 to 5, with higher scores indicating better perceptions of patient-centeredness. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group.

    Time frame: During 2025

  9. Patient reported outcomes (PROMs) - Asthma symptoms

    Asthma symptoms: Asthma Control Test (ACT) 5 questions, each scored from 1 (poor control of asthma) to 5 (complete control of asthma). Higher scores indicate better asthma control. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  10. Patient reported outcomes (PROMs) - Functional problems related to asthma

    Functional problems related to asthma: Asthma Quality of Life Questionnaire (miniAQLQ) Designed to measure the functional problems (physical, emotional, social, and occupational) that are most troublesome to adults with asthma. It includes a series of questions scored from 1 (maximum impairment) to 7 (no impairment), with higher scores indicating better quality of life. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  11. Patient reported outcomes (PROMs) - COPD symptoms

    COPD symptoms: COPD Assessment Test (CAT) Each question is scored from 0 (no impact) to 5 (maximum impact), with the total score ranging from 0 (less impact) to 40 (more impact), indicating the severity of COPD. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  12. Patient reported outcomes (PROMs) - Dyspnea

    Dyspnea: Modified Medical Research Council (mMRC) Dyspnea Scale. It ranges from 0 (no breathlessness except with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing/undressing), with higher scores indicating more severe dyspnea. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  13. Patient reported outcomes (PROMs) - Sino-Nasal symptoms

    Sino-Nasal symptoms: Sino-Nasal Outcome Test (SNOT-22) 22 items, each scored from 0 (no problem) to 5 (problem as bad as it can be). The total score can thus range from 0 (no sinus-related health problems) to 110 (severe sinus-related health problems). This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  14. Patient reported outcomes (PROMs) - Adherence to inhalers

    Adherence to inhalers: Test of Adherence to Inhalers (TAI-12) 12-item questionnaire used to assess a patient's adherence to inhaler medication in respiratory diseases. Each item is scored on a 5-point scale, with higher scores indicating better adherence. The total score ranges from 12 (poor adherence) to 60 (excellent adherence). This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. It will be collected across the entire intervention group and in a randomly selected subset of 50 patients from the control group. \*Depending on whether the primary disorder is asthma or COPD

    Time frame: During 2025

  15. Equity of the intervention

    Access to the service across different population groups: age, ethnicity, gender, socioeconomic status. This outcome is part of a Quintuple Aim assessment of healthcare value generation of the novel integrated care service. Assessed in all individuals

    Time frame: During 2025

  16. Performance of Predictive Modeling for Enhanced Management of Exacerbations

    Model accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic (ROC) curve

    Time frame: During 2025

  17. Performance of the digital support in terms of robustness and usability - Customer Satisfaction

    Customer Satisfaction: Net Promoter Score (NPS) Measures customer loyalty and satisfaction. It is derived from asking customers a single question on a 0-10 scale Assessed in the intervention group only.

    Time frame: During 2025

  18. Performance of the digital support in terms of robustness and usability - Usability

    Usability: System Usability Scale (SUS) Scored on a scale of 0 to 100, scores above 80 is an indicator of excellent usability, while a score below 60 could be problematic and suggests that the design needs improvements. Assessed in the intervention group only.

    Time frame: During 2025

07

Study locations

1 site
  • Fundació de Recerca Clínic Barcelona - Institut d'Investigació Biomèdica August Pi I Sunyer (FRCB-IDIBAPS)
    Barcelona, 08036, Spain
08

References and documents

Publications

  • Herranz C, Martin-Moreno Banegas L, Dana Muzzio F, Siso-Almirall A, Roca J, Cano I. A Practice-Proven Adaptive Case Management Approach for Innovative Health Care Services (Health Circuit): Cluster Randomized Clinical Pilot and Descriptive Observational Study. J Med Internet Res. 2023 Jun 14;25:e47672. doi: 10.2196/47672. PubMed 37314850 ↗
  • Herranz C. A Co-Creation Process Toward Sustainable Adoption of Integrated Care for Prevention of Unplanned Hospitalizations. medRxiv. Published online January 1, 2023:2023.08.03.23293537. doi:10.1101/2023.08.03.23293537
  • Veneroni C, Valach C, Wouters EFM, Gobbi A, Dellaca RL, Breyer MK, Hartl S, Sunanta O, Irvin CG, Schiffers C, Pompilio PP, Breyer-Kohansal R. Diagnostic Potential of Oscillometry: A Population-based Approach. Am J Respir Crit Care Med. 2024 Feb 15;209(4):444-453. doi: 10.1164/rccm.202306-0975OC. PubMed 37972230 ↗
  • Yamagami H, Tanaka A, Kishino Y, Mikuni H, Kawahara T, Ohta S, Yamamoto M, Suzuki S, Ohnishi T, Sagara H. Association between respiratory impedance measured by forced oscillation technique and exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017 Dec 22;13:79-89. doi: 10.2147/COPD.S146669. eCollection 2018. PubMed 29317813 ↗
  • Wu CT, Li GH, Huang CT, Cheng YC, Chen CH, Chien JY, Kuo PH, Kuo LC, Lai F. Acute Exacerbation of a Chronic Obstructive Pulmonary Disease Prediction System Using Wearable Device Data, Machine Learning, and Deep Learning: Development and Cohort Study. JMIR Mhealth Uhealth. 2021 May 6;9(5):e22591. doi: 10.2196/22591. PubMed 33955840 ↗
  • Herranz C. An Adaptive Case Management Approach to Prevent Unplanned Hospital Admissions in a Care Continuum Scenario. Published online 2023.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — During the entirety of the project, it is not allowed to disseminate data. Nonetheless, should a formal request be submitted, it may be permissible to disclose certain elements of the information, albeit not in its totality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 26 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 20, 2024
StartActual
Oct 13, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Aug 31, 2026
Last update
May 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421402
Lead sponsor
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Responsible party
Josep Roca Torrent (Principal Investigator, Institut d'Investigacions Biomèdiques August Pi i Sunyer) — Principal investigator
First posted
May 20, 2024
Start date
Oct 13, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
May 20, 2024

Study contacts

JOSEP ROCA TORRENT, MD, PHD
principal investigator · Institut d'Investigació Biomèdica August Pi I Sunyer (FRCB-IDIBAPS)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion